SCHEMBL5484745

SCHEMBL5484745

Cc1cnc(NCCC2CCCCN2C(=O)OC(C)(C)C)c(=O)n1CCO

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.39
CHEK2 O96017 1/20 0.39
PRMT5 O14744 1/20 0.37
ALOX5AP P20292 1/20 0.37
FEN1 P39748 1/20 0.37
F2 P00734 5/20 0.37
IRAK4 Q9NWZ3 1/20 0.37
KDM1A O60341 1/20 0.36
PDE8B O95263 1/20 0.36
TRPV1 Q8NER1 2/20 0.36
METTL3 Q86U44 1/20 0.35
SYK P43405 1/20 0.34
PRSS1 P07477 1/20 0.33
PRSS2 P07478 1/20 0.33
PRSS3 P35030 1/20 0.33
PDE7B Q9NP56 1/20 0.33
GRM5 P41594 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5483406 0.97 ALOX5AP (0.39) ATMCHEK2PRMT5ALOX5APFEN1
SCHEMBL5483612 0.90 ATM (0.39) ATMCHEK2PRMT5ALOX5APFEN1
SCHEMBL5479364 0.90 CHEK2 (0.39) ATMCHEK2PRMT5ALOX5APFEN1
SCHEMBL5479621 0.87 ATM (0.39) ATMCHEK2PRMT5ALOX5APFEN1
SCHEMBL5471641 0.84 ATM (0.38) ATMCHEK2ALOX5APFEN1F2
SCHEMBL8293870 0.83 ATM (0.40) ATMCHEK2PRMT5ALOX5APFEN1
SCHEMBL5475019 0.81 ATM (0.37) ATMCHEK2PRMT5ALOX5APFEN1
SCHEMBL5479174 0.80 ATM (0.39) ATMCHEK2PRMT5ALOX5APFEN1
SCHEMBL8294709 0.80 CHEK2 (0.36) ATMCHEK2PRMT5ALOX5APFEN1
SCHEMBL5477450 0.79 F2 (0.39) F2IRAK4PRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070099927-A1 Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2007-05-03 US disclosed
US-20070099927-A1 Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2007-05-03 US disclosed
US-20070099927-A1 Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2007-05-03 US disclosed
WO-2005040137-A1 AMINOALKYL-PYRAZINONES AND -PYRIDONES AS THROMBIN INHIBITORS SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099927-A1 Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors F2, F12, SERPINC1 ATM 1490/4885CHEK2 2556/4885PRMT5 931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.